Dermata Therapeutics, Inc.
Company Details
Status: Public
Employees: 1-10
Location:
Lexington, Massachusetts, United States of America
Type:
sample
Technology:
sample
sample
About: Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Dermata Therapeutics, Inc. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.